LONDON — In the year-plus since Najat Khan joined the AI-focused drug developer Recursion Pharmaceuticals, she has helped push forward — and prune — the company’s pipeline, and navigate its merger with Exscientia.
Now Khan, who was hired as Recursion’s chief commercial officer and R&D head, is set to take the reins as CEO in the new year.
Current CEO Chris Gibson, one of the founders of the company, announced earlier this month that he would step down, telling STAT that Recursion, which is moving toward later-stage development programs, needed a leader with a different skill set. Gibson is becoming board chair.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply